

**BPCL**

Refer to important disclosures at the end of this report

# Earnings beat estimates amid higher inventory gains, GRM steady

<b>CMP</b>	<b>Target Price</b>
<b>Rs 326</b> as of (May 26, 2022)	<b>Rs 415 (▼)</b> 12 months
<b>Rating</b>	<b>Upside</b>
<b>BUY (■)</b>	<b>27.3 %</b>

- BPCL reported Q4FY22 standalone EBITDA/PAT of Rs44.5bn/Rs21.3bn (up 4%, down 13% qoq). EBITDA/PAT beat our estimates by 38/43% due to a 12% GRM beat and 2x higher marketing inventory gains, partly offset by higher opex.
- Reported GRM came in higher at USD15.3/bbl (vs. USD13.6 est.). We believe core GRM could be ~USD10/bbl. Refinery volume was healthy at 8.12mmt or 118% utilization. Domestic sales volume growth of 6% yoy was the best among OMCs and the industry.
- Marketing inventory gain in Q4 was Rs31.8bn (vs. Rs15bn est), with BPCL's blended margin at Rs0.65/kg (lower than Rs0.9/kg est). Implied net debt rose 25% yoy/26% qoq to ~Rs276bn (incl lease liabilities), with interest costs up 20% qoq to Rs5.3bn.
- We cut our FY23E EPS by 19%, lowering marketing margins ahead, though partly offset by higher GRMs. We reduce our Mar'23E SOTP-based TP by 10% to Rs415, reducing the core business blended FY24E EV/EBITDA multiple from 5.6x to 5.4x. Maintain Buy.

- Highlights:** BPCL's gross profit of Rs111bn in Q4 was 22% above our estimate, though Other Expenditure rose 18% yoy/22% qoq to Rs57.4bn (16% above est). Depreciation also rose 9% qoq. The forex loss was lower than expected at Rs2.0bn, while the tax rate was higher at 29.9% due to provisions from earlier years. Petrol/diesel sales volume growth was 4%/3% yoy, better than industry numbers. For FY22, S/A EBITDA/APAT was Rs164bn/Rs88bn, down 8%/30% yoy on the back of an over 30% drop in marketing margins. Reported GRM rose from USD4.1/bbl to USD9.1/bbl. Refining throughput rose by 14% to 30.1mmt, while marketing sales volumes grew by 10% to 44.6mmt. Capex, as per PPAC data, was Rs114.5bn. The board recommended a final dividend of Rs6/sh (Rs16/sh total in FY22), implying a payout of 39% for the year.
- Guidance:** Bina Refinery (BORL) posted a PAT of Rs8.92bn and GRM of ~USD11/bbl in FY22. The merger was in process. BPCL's FY23 capex guidance is ~Rs100bn. The CWIP provision was in Other Expenditure. BPCL's refining inventory gain was similar to peers (as per our estimate, it implies ~USD10/bbl of core GRM). The scheme details for the Rs200/cy PMUY subsidy are yet to come, hence it is not implemented yet. Govt subsidy outstanding was Rs2bn as of FY22-end.
- Valuation:** We value BPCL on a SOTP basis, with investments at a 30% holdco discount. We slightly lowered the target EV/EBITDA multiple from 5.6x to 5.4x with no divestment premium anymore. While the current scenario is weak with negative auto-fuel margins, we maintain Buy owing to reasonable valuations and expectations of a gradual recovery in margins to normative levels. Key risks: adverse commodity/currency/policies/capex.

Please see our sector model portfolio (Emkay Alpha Portfolio): [Oil & Gas \(Page 7\)](#)

## Financial Snapshot (Standalone)

(Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Revenue	23,25,533	36,22,768	48,65,723	41,39,077	39,61,021
EBITDA	1,79,176	1,64,208	1,45,881	1,70,522	1,78,443
EBITDA Margin (%)	7.7	4.5	3.0	4.1	4.5
APAT	1,26,767	88,456	76,310	93,735	97,094
EPS (Rs)	60.6	41.5	35.8	44.0	45.6
EPS (% chg)	216.1	(31.4)	(13.7)	22.8	3.6
ROE (%)	15.5	17.6	14.7	16.4	15.5
P/E (x)	5.4	7.9	9.1	7.4	7.2
EV/EBITDA (x)	4.9	5.9	6.3	5.5	5.1
P/BV (x)	1.3	1.4	1.3	1.2	1.1

Source: Company, Emkay Research


Change in Estimates	
EPS Chg FY23E/FY24E (%)	-19/-4
Target Price change (%)	(9.8)
Target Period (Months)	12
Previous Reco	BUY

Emkay vs Consensus		
EPS Estimates		
	FY23E	FY24E
Emkay	35.8	44.0
Consensus	42.5	56.4
Mean Consensus TP (12M)	Rs 471	

Stock Details	
Bloomberg Code	BPCL IN
Face Value (Rs)	10
Shares outstanding (mn)	2,169
52 Week H/L	470 / 324
M Cap (Rs bn/USD bn)	707 / 9.13
Daily Avg Volume (nos.)	5,610,456
Daily Avg Turnover (US\$ mn)	26.0

Shareholding Pattern Mar '22	
Promoters	53.0%
FIIIs	13.7%
DIIIs	19.9%
Public and Others	13.5%

Price Performance				
(%)	1M	3M	6M	12M
<b>Absolute</b>	(12)	(3)	(18)	(26)
<b>Rel. to Nifty</b>	(7)	1	(11)	(29)



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

**Sabri Hazarika**  
sabri.hazarika@emkayglobal.com  
+91 22 6612 1282

**Harsh Maru**  
harsh.maru@emkayglobal.com  
+91 22 6612 1336

## Exhibit 1: Actual vs. Estimates (Q4FY22)

Rs bn	Actual	Estimates (Emkay)	Consensus Estimates (Bloomberg)	Variation		Comments
				Emkay	Consensus	
Total Revenue	1,088	1,366	1,259	-20%	-14%	
Adjusted EBITDA	44	32	40	38%	12%	Higher inventory gains/GRMs
EBITDA Margin (%)	4.1%	2.4%	3.1%	170bps	90bps	
Adjusted Net Profit	21	15	29	43%	-27%	

Source: Company, Emkay Research

## Exhibit 2: Quarterly summary

Rs mn	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	YoY	QoQ	FY21	FY22	YoY
Revenue	7,68,905	7,09,213	8,15,367	10,10,453	10,87,736	41%	8%	23,25,533	36,22,768	56%
COGS	6,58,369	6,26,675	7,19,577	9,12,067	9,76,737	48%	7%	19,53,209	32,35,055	66%
Gross Profit	1,10,536	82,538	95,790	98,386	1,10,999	0%	13%	3,72,324	3,87,712	4%
Opex	59,152	49,544	51,012	55,899	66,536	12%	19%	1,92,582	2,22,991	16%
Total Expenditure	7,17,521	6,76,218	7,70,590	9,67,966	10,43,273	45%	8%	21,45,791	34,58,046	61%
EBITDA	51,384	32,994	44,777	42,487	44,463	-13%	5%	1,79,742	1,64,721	-8%
Depreciation	9,998	11,446	11,681	11,680	12,736	27%	9%	39,781	47,543	20%
Interest	4,776	4,867	3,940	4,460	5,338	12%	20%	13,284	18,605	40%
Other Income	16,266	4,517	6,292	6,826	5,976	-63%	-12%	40,799	23,611	-42%
Exceptional Items	69,206	(771)	-	-	-			56,701	(771)	
Forex Gain/(Losses)	292	(467)	513	(357)	(1,970)			1,998	(2,280)	
PBT	1,22,374	19,961	35,961	32,817	30,395	-75%	-7%	2,26,176	1,19,134	-47%
Tax	2,973	4,945	9,020	8,192	9,090	206%	11%	35,759	31,247	
PAT	1,19,401	15,016	26,941	24,625	21,305	-82%	-13%	1,90,417	87,887	-54%
Adjusted PAT	39,770	15,596	26,941	24,625	21,305	-46%	-13%	1,19,244	88,467	-26%
Adjusted EPS (Rs)	19.0	7.3	12.7	11.6	10.0	-47%	-13%	59.4	41.5	-30%
Tax Rate	2%	25%	25%	25%	30%			16%	26%	
Core EBITDA*	14,964	17,344	36,007	49,217	(7,307)			1,05,432	95,261	-10%
Core PAT*	12,309	4,151	19,955	29,847	(14,515)			69,689	39,438	-43%
Core EPS (Rs)*	5.9	1.9	9.4	14.0	(6.8)			35.1	18.5	-47%
Refining Volumes (mmt)	8.4	6.8	7.2	8.0	8.1	-3%	2%	26.4	30.1	14%
Reported GRM (USD/bbl)	6.6	4.1	6.0	9.7	15.3	130%	57%	4.1	9.1	121%
Core GRM (USD/bbl)*	2.6	2.1	4.4	8.0	10.8	318%	35%	1.8	6.5	253%
Adjusted Refining EBITDA*	20,851	6,668	14,690	33,160	58,858	182%	77%	24,569	1,13,376	361%
Marketing Volumes (mmt)	11.8	9.9	10.4	11.7	12.6	7%	8%	40.7	44.6	10%
Diesel	5.0	4.4	4.3	5.0	5.2	3%	5%	17.5	18.8	8%
Petrol	2.1	1.8	2.1	2.2	2.1	4%	-2%	7.2	8.1	13%
Marketing Margin (Rs/mt)	5,112	5,702	6,514	5,781	645	-87%	-89%	6,478	4,484	-31%
Adjusted Marketing EBITDA*	28,483	24,036	27,879	6,792	(17,133)			1,47,868	41,574	-72%
Marketing Inventory Gain/(Losses)	18,290	8,150	2,270	(14,230)	31,770	74%	-323%	42,510	27,960	
Pipeline Volumes (mmt)	4.3	4.4	4.6	5.2	5.5	27%	6%	14.9	19.6	32%
Implied Pipeline EBITDA*	2,050	2,291	2,208	2,535	2,737	34%	8%	7,304	9,771	34%
Gross Debt	3,41,600	2,15,771	2,89,698	3,22,474	3,27,171	-4%	1%	3,41,600	3,27,171	-4%
Implied Net Debt	2,20,775	74,901**	1,29,984	2,19,149	2,76,236	25%	26%	2,20,775	2,76,236	25%
Net Under-recovery	-	-	-	-	-	-	-	-	-	-

Source: Company, Emkay Research;

\*Note: OMCs have discontinued reporting inventory gain/loss figures (BPCL gives marketing though), hence these numbers are estimates. \*\*BPCL's gross debt includes lease liabilities except for Q1FY22

## Exhibit 3: Change in assumptions

	FY23E			FY24E			FY25E
	Previous	Revised	Variance	Previous	Revised	Variance	Introduced
GRM (USD/bbl)	6.0	12.0	100%	6.1	10	65%	9.5
Marketing Margin (Rs/mt)	5,615	3,587	-36%	5,726	4,910	-14%	5,275
Growth	5.3%	-15.2%	-2050bps	2.0%	36.9%	3490bps	7.4%
Marketing Sales (mmt)	46	46	1%	47	48	1%	49
Growth	5.0%	3.7%	-120bs	3.2%	3.3%	10bps	2.6%

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/26/2022 12:35 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Exhibit 4: Change in estimates**

(Rs bn)	FY23E			FY24E			FY25E
	Previous	Revised	Variance	Previous	Revised	Variance	Previous
Revenue	5,570	4,866	-13%	4,541	4,139	-9%	3,961
EBITDA	161	146	-10%	170	171	0%	178
EBITDA Margins	2.9%	3.0%	10bps	3.7%	4.1%	40bps	4.5%
PAT	94	76	-19%	97	94	-4%	97
EPS (Rs)	44.2	35.8	-19%	45.7	44.0	-4%	45.6

Source: Company, Emkay Research

**Valuation****Exhibit 5: SOTP Valuation – Mar'23E**

Components	Basis	Mar'24E EBITDA	Multiple(x)	EV (Rs bn)	EV/Sh (Rs)	Comments
Refining Standalone	EV/EBITDA	141	5.5	774	364	
Pipelines Standalone	EV/EBITDA	9	5.5	51	24	
Petrochemicals Standalone	EV/EBITDA	0		-	-	
Marketing Standalone	EV/EBITDA	20	5.0	101	48	
<b>Core Business EV</b>		<b>171</b>	<b>5.4</b>	<b>927</b>	<b>435</b>	Blended Multiple at 5.4x
Less: Adj. Net Debt (Mar23 End)				187	88	
<b>Core Business Valuation</b>				<b>740</b>	<b>347</b>	
Value of BORL Stake	EV/EBITDA			19	9	
Value of Mozambique Stake	Transaction Value			36	17	At 30% Discount
Value of Listed Investments	TP			89	42	At 30% HoldCo Discount
<b>Target Price-Fair Value</b>					<b>415</b>	

Source: Company, Emkay Research

**Exhibit 6: Schedule and value of Investments – Mar'23E**

Listed	Type	Basis of Valuation	TP/CMP (Rs/sh)	Equity Value (Rs bn)	BPCL Stake	Pro-rata Value (Rs bn)	HoldCo Discount	Contr. to SOTP (Rs bn)	Per Share Value (Rs)
IGL	JV	TP (Emkay)	450	315	22.5%	71	30%	50	23
PLNG	JV	TP (Emkay)	255	383	12.5%	48	30%	33	16
Oil India	Financial	TP (Emkay)	335	363	2.5%	9	30%	6	3
<b>Total Listed</b>						<b>128</b>		<b>89</b>	<b>42</b>

Source: Company, Emkay Research;

**Exhibit 7: Value of Upstream-BORL stake**

Components	Basis	Mar'24E EBITDA (Rs bn)	Multiple (x)	EV (Rs bn)	BPCL stake	Net Debt (Rs bn)	Equity Value (Rs/bn)	Equity Value (Rs/sh)
Bina Refinery (BORL)	EV/EBITDA	22	5.0	111	100%	93	19	9
Mozambique Upstream Area 1	30% discount to last transaction value			76	10%	40	36	17

Source: Company, Emkay Research

**Key Financials (Standalone)****Income Statement**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
<b>Revenue</b>	<b>23,25,533</b>	<b>36,22,768</b>	<b>48,65,723</b>	<b>41,39,077</b>	<b>39,61,021</b>
<b>Expenditure</b>	<b>21,46,357</b>	<b>34,58,560</b>	<b>47,19,842</b>	<b>39,68,554</b>	<b>37,82,577</b>
<b>EBITDA</b>	<b>1,79,176</b>	<b>1,64,208</b>	<b>1,45,881</b>	<b>1,70,522</b>	<b>1,78,443</b>
Depreciation	39,781	47,543	51,889	56,554	61,954
<b>EBIT</b>	<b>1,39,396</b>	<b>1,16,665</b>	<b>93,992</b>	<b>1,13,968</b>	<b>1,16,489</b>
Other Income	41,365	24,124	25,927	29,431	31,703
Interest expenses	13,284	18,605	17,900	18,084	18,387
<b>PBT</b>	<b>1,67,478</b>	<b>1,22,185</b>	<b>1,02,019</b>	<b>1,25,314</b>	<b>1,29,804</b>
Tax	99,408	30,679	25,709	31,579	32,711
Extraordinary Items	58,698	(3,050)	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
<b>Reported Net Income</b>	<b>1,90,417</b>	<b>87,887</b>	<b>76,310</b>	<b>93,735</b>	<b>97,094</b>
<b>Adjusted PAT</b>	<b>1,26,767</b>	<b>88,456</b>	<b>76,310</b>	<b>93,735</b>	<b>97,094</b>

**Balance Sheet**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
Equity share capital	20,929	21,295	21,295	21,295	21,295
Reserves & surplus	5,24,516	4,75,403	5,21,189	5,77,430	6,35,687
<b>Net worth</b>	<b>5,45,446</b>	<b>4,96,698</b>	<b>5,42,484</b>	<b>5,98,725</b>	<b>6,56,981</b>
<b>Minority Interest</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Loan Funds</b>	<b>3,41,603</b>	<b>3,27,171</b>	<b>2,67,171</b>	<b>2,95,171</b>	<b>2,80,171</b>
Net deferred tax liability	44,716	48,827	52,091	55,388	58,718
<b>Total Liabilities</b>	<b>9,31,764</b>	<b>8,72,696</b>	<b>8,61,746</b>	<b>9,49,284</b>	<b>9,95,870</b>
<b>Net block</b>	<b>6,39,363</b>	<b>6,94,947</b>	<b>7,46,388</b>	<b>7,98,825</b>	<b>8,31,660</b>
<b>Investment</b>	<b>1,90,908</b>	<b>2,25,911</b>	<b>2,28,614</b>	<b>2,31,353</b>	<b>2,34,129</b>
<b>Current Assets</b>	<b>5,02,174</b>	<b>5,50,969</b>	<b>7,16,793</b>	<b>6,22,966</b>	<b>6,00,459</b>
Cash & bank balance	70,535	8,345	4,129	8,937	10,225
Other Current Assets	0	0	0	0	0
<b>Current liabilities &amp; Provision</b>	<b>4,74,176</b>	<b>6,32,430</b>	<b>8,60,018</b>	<b>7,24,839</b>	<b>6,91,567</b>
<b>Net current assets</b>	<b>27,998</b>	<b>(81,461)</b>	<b>(1,43,226)</b>	<b>(1,01,873)</b>	<b>(91,108)</b>
Misc. exp	0	0	0	0	0
<b>Total Assets</b>	<b>9,31,764</b>	<b>8,72,696</b>	<b>8,61,746</b>	<b>9,49,284</b>	<b>9,95,870</b>

**Cash Flow**

Y/E Mar (Rs mn)	FY21	FY22	FY23E	FY24E	FY25E
<b>PBT (Ex-Other income) (NI+Dep)</b>	<b>1,26,112</b>	<b>98,060</b>	<b>76,092</b>	<b>95,884</b>	<b>98,102</b>
Other Non-Cash items	14,765	15,564	0	0	0
Chg in working cap	58,525	51,381	60,813	(33,248)	(6,147)
<b>Operating Cashflow</b>	<b>2,00,298</b>	<b>2,00,493</b>	<b>1,80,985</b>	<b>1,05,695</b>	<b>1,39,586</b>
Capital expenditure	(88,081)	(62,930)	(1,00,000)	(1,00,000)	(95,000)
<b>Free Cash Flow</b>	<b>1,12,217</b>	<b>1,37,562</b>	<b>80,985</b>	<b>5,695</b>	<b>44,586</b>
Investments	(17,565)	(35,003)	(2,703)	(2,739)	(2,776)
Other Investing Cash Flow	89,583	(1,903)	0	0	0
<b>Investing Cashflow</b>	<b>25,302</b>	<b>(75,712)</b>	<b>(76,776)</b>	<b>(73,309)</b>	<b>(66,073)</b>
Equity Capital Raised	1,260	365	0	0	0
Loans Taken / (Repaid)	(1,36,584)	(14,433)	(60,000)	28,000	(15,000)
Dividend paid (incl tax)	(42,613)	(1,44,828)	(30,524)	(37,494)	(38,837)
Other Financing Cash Flow	34,997	(9,471)	0	0	0
<b>Financing Cashflow</b>	<b>(1,56,223)</b>	<b>(1,86,971)</b>	<b>(1,08,424)</b>	<b>(27,578)</b>	<b>(72,224)</b>
<b>Net chg in cash</b>	<b>69,377</b>	<b>(62,190)</b>	<b>(4,216)</b>	<b>4,808</b>	<b>1,288</b>
Opening cash position	1,158	70,535	8,345	4,129	8,937
<b>Closing cash position</b>	<b>70,535</b>	<b>8,345</b>	<b>4,129</b>	<b>8,937</b>	<b>10,225</b>

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 05/26/2022 12:35 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY&lt;GO&gt;. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

**Key Ratios**

<b>Profitability (%)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
EBITDA Margin	7.7	4.5	3.0	4.1	4.5
EBIT Margin	6.0	3.2	1.9	2.8	2.9
Effective Tax Rate	59.4	25.1	25.2	25.2	25.2
Net Margin	2.9	2.5	1.6	2.3	2.5
ROCE	20.1	15.6	13.8	15.8	15.2
ROE	15.5	17.6	14.7	16.4	15.5
RoIC	9.5	14.5	11.7	13.2	12.3

<b>Per Share Data (Rs)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
EPS	60.6	41.5	35.8	44.0	45.6
CEPS	51.5	65.3	60.2	70.6	74.7
BVPS	260.6	233.3	254.8	281.2	308.5
DPS	79.0	16.0	14.3	17.6	18.2

<b>Valuations (x)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
PER	5.4	7.9	9.1	7.4	7.2
P/CEPS	6.3	5.0	5.4	4.6	4.4
P/BV	1.3	1.4	1.3	1.2	1.1
EV / Sales	0.4	0.3	0.2	0.2	0.2
EV / EBITDA	4.9	5.9	6.3	5.5	5.1
Dividend Yield (%)	24.2	4.9	4.4	5.4	5.6

<b>Gearing Ratio (x)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
Net Debt/ Equity	0.4	0.6	0.4	0.4	0.3
Net Debt/EBIDTA	1.1	1.7	1.5	1.4	1.2
Working Cap Cycle (days)	26.6	13.9	13.9	13.9	13.9

<b>Growth (%)</b>	<b>FY21</b>	<b>FY22</b>	<b>FY23E</b>	<b>FY24E</b>	<b>FY25E</b>
Revenue	(18.2)	55.8	34.3	(14.9)	(4.3)
EBITDA	115.8	(8.4)	(11.2)	16.9	4.6
EBIT	208.8	(16.3)	(19.4)	21.3	2.2
PAT	609.7	(53.8)	(13.2)	22.8	3.6

<b>Quarterly (Rs mn)</b>	<b>Q4FY21</b>	<b>Q1FY22</b>	<b>Q2FY22</b>	<b>Q3FY22</b>	<b>Q4FY22</b>
Revenue	7,68,905	7,09,213	8,15,367	10,10,453	10,87,736
EBITDA	51,384	32,994	44,777	42,487	44,463
<b>EBITDA Margin (%)</b>	<b>6.7</b>	<b>4.7</b>	<b>5.5</b>	<b>4.2</b>	<b>4.1</b>
PAT	1,19,401	15,016	26,941	24,625	21,305
<b>EPS (Rs)</b>	<b>57.1</b>	<b>7.1</b>	<b>12.7</b>	<b>11.6</b>	<b>10.0</b>

Source: Company, Emkay Research

<b>Shareholding Pattern (%)</b>	<b>Mar-21</b>	<b>Jun-21</b>	<b>Sep-21</b>	<b>Dec-21</b>	<b>Mar-22</b>
Promoters	53.0	53.0	53.0	53.0	53.0
FIs	12.4	12.6	12.0	12.7	13.7
DIs	23.3	22.4	21.7	21.1	19.9
Public and Others	11.3	12.0	13.3	13.2	13.5


Source: Capitaline

## RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
22-May-22	333	460	12m	Buy	Sabri Hazarika
09-Mar-22	343	460	12m	Buy	Sabri Hazarika
02-Feb-22	382	515	12m	Buy	Sabri Hazarika
25-Dec-21	372	510	12m	Buy	Sabri Hazarika
23-Nov-21	398	510	12m	Buy	Sabri Hazarika
31-Oct-21	418	510	12m	Buy	Sabri Hazarika
14-Aug-21	455	535	12m	Buy	Sabri Hazarika
26-Jul-21	456	525	12m	Buy	Sabri Hazarika
23-Jun-21	470	525	12m	Buy	Sabri Hazarika
29-May-21	472	525	12m	Buy	Sabri Hazarika
28-May-21	472	525	12m	Buy	Sabri Hazarika
23-Apr-21	423	495	12m	Buy	Sabri Hazarika
22-Mar-21	439	495	12m	Buy	Sabri Hazarika
18-Mar-21	427	495	12m	Buy	Sabri Hazarika
02-Mar-21	469	495	12m	Buy	Sabri Hazarika
09-Feb-21	419	495	12m	Buy	Sabri Hazarika
16-Dec-20	400	490	12m	Buy	Sabri Hazarika
26-Nov-20	378	480	12m	Buy	Sabri Hazarika
30-Oct-20	354	480	12m	Buy	Sabri Hazarika
28-Sep-20	385	480	12m	Buy	Sabri Hazarika
23-Sep-20	388	480	12m	Buy	Sabri Hazarika
06-Sep-20	403	480	12m	Buy	Sabri Hazarika
15-Aug-20	413	480	12m	Buy	Sabri Hazarika
17-Jul-20	444	480	12m	Buy	Sabri Hazarika
04-Jun-20	357	480	12m	Buy	Sabri Hazarika
03-Jun-20	349	570	12m	Buy	Sabri Hazarika
06-May-20	344	570	12m	Buy	Sabri Hazarika
11-Mar-20	404	570	12m	Buy	Sabri Hazarika
14-Feb-20	476	570	12m	Buy	Sabri Hazarika
24-Jan-20	466	590	12m	Buy	Sabri Hazarika
04-Dec-19	501	590	12m	Buy	Sabri Hazarika
08-Nov-19	503	590	12m	Buy	Sabri Hazarika
25-Oct-19	524	570	12m	Buy	Sabri Hazarika
14-Oct-19	486	570	12m	Buy	Sabri Hazarika
23-Sep-19	451	485	12m	Buy	Sabri Hazarika
13-Aug-19	343	420	12m	Buy	Sabri Hazarika
10-Jun-19	390	420	12m	Buy	Sabri Hazarika

Source: Company, Emkay Research

## RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

## Emkay Alpha Portfolio – Oil & Gas



**Analyst: Sabri Hazarika**

### Contact Details

sabri.hazarika@emkayglobal.com  
+91 22 6612 1282

### Sector

Oil & Gas

### Analyst bio

Sabri Hazarika holds an MBA and comes with 12 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.

### EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight based on Current NAV	Change vs last published EAP (bps)
<b>Oil &amp; Gas</b>	<b>11.87</b>	<b>11.87</b>	<b>0%</b>	<b>0</b>	<b>100.00</b>	
BPCL	0.35	0.36	2%	1	3.00	23
<b>GAIL</b>	<b>0.29</b>	<b>0.23</b>	<b>-23%</b>	<b>-7</b>	<b>1.90</b>	<b>-78</b>
Gujarat Gas	0.10	0.09	-5%	0	0.80	10
<b>Gujarat State Petronet</b>	<b>0.08</b>	<b>0.06</b>	<b>-25%</b>	<b>-2</b>	<b>0.50</b>	<b>-15</b>
Gulf Oil Lubricants	0.00	0.00	NA	0	0.00	0
<b>HPCL</b>	<b>0.16</b>	<b>0.12</b>	<b>-28%</b>	<b>-5</b>	<b>1.00</b>	<b>-24</b>
Indian Oil	0.32	0.25	-22%	-7	2.10	-36
Indraprastha Gas	0.14	0.11	-22%	-3	0.90	-6
<b>Petronet LNG</b>	<b>0.18</b>	<b>0.14</b>	<b>-20%</b>	<b>-4</b>	<b>1.20</b>	<b>-15</b>
Oil India	0.09	0.08	-8%	-1	0.67	-9
<b>ONGC</b>	<b>0.58</b>	<b>0.65</b>	<b>12%</b>	<b>7</b>	<b>5.50</b>	<b>6</b>
Reliance Industries	9.58	9.78	2%	20	82.40	141
<b>Cash</b>	<b>0.00</b>	<b>0.00</b>	<b>NA</b>	<b>0</b>	<b>0.03</b>	<b>3</b>

Source: Emkay Research

■ High Conviction/Strong Over Weight ■ High Conviction/Strong Under Weight

### Sector portfolio NAV

	Base					Latest
	1-Apr-19	25-May-21	24-Nov-21	22-Feb-22	21-Apr-22	24-May-22
EAP - Oil & Gas	100.0	127.4	149.1	149.2	171.0	159.3
BSE200 Neutral Weighted Portfolio (ETF)	100.0	126.7	148.3	148.1	169.9	158.2

\*Performance measurement base date 1<sup>st</sup> April 2019


Source: Emkay Research

### Price Performance (%)

	1m	3m	6m	12m
EAP - Oil & Gas	-6.8%	6.8%	6.8%	25.1%
BSE200 Neutral Weighted Portfolio (ETF)	-6.9%	6.8%	6.7%	24.9%

Source: Emkay Research

### NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): [Nifty](#)

Please see our model portfolio (Emkay Alpha Portfolio): [SMID](#)

“Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals”

## Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Completed Date: 26 May 2022 11:09:51 (SGT)

Dissemination Date: 26 May 2022 11:10:51 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com)

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.



**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 26, 2022
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report
- Disclosure of previous investment recommendation produced:**
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 26, 2022.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 26, 2022
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 26, 2022

**RESTRICTIONS ON DISTRIBUTION**

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 <sup>th</sup> Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com